Clinical trials: vaccines, open to volunteers
Seasonal Influenza
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children
The purpose of this study is to evaluate safety, reactogenicity, and immunogenicity of mRNA-1010 in healthy children (9 to <18 years of age).
- Trial name
- NCT07870330
- Testing
- mRNA-1010, Fluarix Trivalent
- Where
- 6 sites in United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza, COVID-19
Flu COVID Vaccine Views
This study addresses a critical evidence gap relevant to implementation strategies for combination vaccines in health care settings.
- Conditions
- Influenza, COVID-19, Vaccination Willingness
- Trial name
- NCT07871448
- Testing
- Survey
- Where
- 2 sites in United States
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- George Washington University
Cardiovascular Disease
A Study on the Impact of Recombinant Zoster Vaccine on Major Adverse Cardiovascular Events in Adults >=50 Years of Age With Established Cardiovascular Disease or With >=2 Cardiovascular Risk Factors
This study aims to evaluate the effect of the recombinant zoster vaccine (RZV) on the occurrence of clinically important cardiovascular (heart and blood vessel) events, with a focus on major adverse cardiovascular events (MACE)…
- Trial name
- NCT07872046
- Testing
- RZV vaccine
- Volunteers
- 16,390 people
- Sponsor
- GlaxoSmithKline
Adult, Healthy Participants
A Study to Learn About the Safety and Immune Responses of RSVpreF in Older Adults
The purpose of this study is to learn about the safety, tolerability, and immune response of the RSVpreF vaccine in healthy older adults. Participants will take part in this study for about 6 months.
- Trial name
- NCT07819097
- Testing
- RSVpreF
- Where
- 15 sites in United States, China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza, Human
A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age
This clinical trial will study an investigational seasonal influenza vaccine in adults 18 to 64 years of age. The vaccine is based on messenger ribonucleic acid, also called mRNA.
- Trial name
- NCT07851246
- Testing
- mRNA Seasonal Flu vaccine, Comparator 1, Comparator 2
- Where
- 12 sites in United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
Background: Shingles is a painful, blistering rash caused by the same virus that causes chickenpox. Shingrix is a vaccine approved to prevent shingles in healthy adults over age 50 and in immunocompromised adults over age 18.
- Trial name
- NCT05580458
- Testing
- Shingrix
- Where
- United States
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Papillomavirus Vaccines
ReMARK: Addressing Disparities in Rural HPV-related Cancer Prevention
There are three main objectives of the protocol. First, we will evaluate the added clinical- and cost- effectiveness of parent-targeted motivational aids (reminder/recall and phone-based MI) alone and when combined with…
- Trial name
- NCT06535139
- Testing
- Brief training, Parent-targeted motivational aids, Healthcare access
- Where
- United States
- Volunteers
- 4,630 people
- Sponsor
- University of Florida
Healthy
Safety and Immunogenicity of V540B in Healthy Adults (V540B-002).
Researchers are looking for new ways to prevent cancers related to human papillomavirus (HPV). HPV is a common virus that can cause an infection. There are many different types of HPV.
- Trial name
- NCT06623409
- Testing
- GARDASIL®9 (G9), V540B
- Where
- 4 sites in United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Severe Acute Malnutrition in Childhood, Pneumococcal Disease
Opportunistic Pneumococcal Immunisation Trial in MALnutrition
The goal of the OPTIMAL clinical trial is to learn if a dose of a pneumococcal conjugate vaccine (PCV) generates a good immune response in young children who are in hospital with severe acute malnutrition.
- Conditions
- Severe Acute Malnutrition in Childhood, Pneumococcal Disease, Pneumococcal Vaccines, Pneumococcal Infection
- Trial name
- OPTIMAL (NCT06817421)
- Testing
- Pneumococcal conjugate vaccine, Typhoid conjugate vaccine
- Where
- Timor-Leste
- Volunteers
- 214 people
- Sponsor
- Nick Fancourt
mRNA Vaccination, Hepatocellular Carcinoma
SARS-CoV-2 mRNA Vaccination in Patients With Hepatocellular Carcinoma Treated With Immune Checkpoint Inhibitors
A multicenter retrospective cohort analysis in Austria Primary Objective: To assess whether receiving an mRNA COVID-19 vaccine within 3 months before starting ICI (Immune checkpoint inhibitors) therapy improves best overall…
- Conditions
- mRNA Vaccination, Hepatocellular Carcinoma, Checkpoint Inhibitor
- Trial name
- CoVaCheck (NCT07341321)
- Where
- 5 sites in Austria
- Volunteers
- 200 people
- Sponsor
- Medical University of Graz
Spirometry
The INTERvening for LUNG Health Trial
This research study is being done to find out whether a community health volunteer-delivered, multi-component program can improve lung health for people at risk of chronic respiratory diseases (such as asthma or COPD) in…
- Trial name
- INTERLUNG (NCT07540000)
- Testing
- Community health worker-delivered multi-component respiratory health intervention
- Where
- 2 sites in United States, Nepal
- Volunteers
- 800 people
- Sponsor
- Johns Hopkins University
Influenza Vaccination
Family Physician Nudges for Influenza Vaccination Among Older Adults
The goal of this clinical trial is to learn if a family-physician nudge intervention works to improve influenza vaccination among adults aged 55 years and older in China.
- Trial name
- NCT07864597
- Testing
- Family Physician Influenza Vaccination Nudge
- Volunteers
- 5,250 people, healthy volunteers welcome
- Sponsor
- Fudan University
Febrile Illness
Knowledge, Attitudes, Perceptions and Behaviors of Healthcare Professionals and the General Population Regarding Vaccination During Febrile Illness
Patients and healthcare professionals often lack adequate information regarding the possibility of vaccinating during febrile illnesses due to limited data.
- Trial name
- NCT06959420
- Testing
- Questionnaire
- Where
- France
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Respiratory Syncytial Virus (RSV), Respiratory Infection Virus
THRIVE - Trial of Passive Humoral RSV Immunity for Value and Effectiveness
RSV is a leading cause of severe respiratory illness and hospitalisation for young children, with particularly high rates of RSV respiratory infection observed amongst Aboriginal and Torres Strait Islander children living in…
- Trial name
- THRIVE (NCT07578298)
- Testing
- Nirsevimab (RSV-specific monoclonal antibody)
- Where
- Australia
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Menzies School of Health Research
Bone Marrow Transplant, Stem Cell Transplant
Shingrix In Recipients of Allogeneic Transplants
This research is designed to determine if the adjuvanted recombinant glycoprotein E (gE) herpes zoster (HZ) vaccine (Shingrix) has acceptable immunogenicity and safety in people who have undergone allogeneic stem cell transplant…
- Trial name
- Allo (NCT05775718)
- Testing
- Zoster Vaccine Recombinant
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Colorado, Denver
EBV, Epstein-Barr Virus Infection
Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection
Background: Epstein-Barr virus (EBV) is the primary cause of infectious mononucleosis, commonly known as mono. EBV infects more than 90% of the world s population.
- Conditions
- EBV, Epstein-Barr Virus Infection, Infectious Mononucleosis, Mono
- Trial name
- NCT06908096
- Testing
- EBV gp350-ferritin vaccine with ALFQ adjuvant, EBV gH/gL/gp42-ferritin nanoparticle vaccine with ALFQ adjuvant
- Where
- United States
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cholera Vaccination Reaction
Phase 1b Ascending Dose Study of PanChol in Healthy Volunteers
Cholera is a serious diarrheal disease that can be fatal within hours of onset. The current available cholera vaccines to prevent the disease are not very effective.
- Trial name
- PanChol (NCT07107516)
- Testing
- PanChol
- Where
- Zambia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Centre for Infectious Disease Research in Zambia
Misinformation, Lenacapavir
Protecting Against Lenacapavir Misinformation With Young Women in Gauteng, South Africa ( PROTECT-L)
Adolescent girls and young women (AGYW) in South Africa remain disproportionately affected by HIV, with prevalence among 15-24-year-olds at 9.4% in 2024 despite expanded access to condoms, HIV testing, and oral PrEP.
- Trial name
- PROTECT-L (NCT07518914)
- Testing
- Diabetes information, Enhanced inoculation message
- Where
- South Africa
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Recurrent Prostate Cancer, Prostate Cancer
IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy
Background: Biochemically recurrent prostate cancer (BCR) occurs when prostate-specific antigen (PSA) levels in the blood rise after surgery or radiation. BCR affects 30,000 to 50,000 men each year.
- Trial name
- NCT07686380
- Testing
- N-803, ETBX-71 Vaccine, 18F-DCFPyL
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Diptheria Immunization, Tetanus Immunization
Safety and Immunogenicity of a Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Recombinant Poliomyelitis and Haemophilus Influenzae Type b (Hib) Vaccine (SIIPL DTwP-HepB-rPV-Hib)
This is a Phase I/II, double-blind, randomized, active controlled, multi-centric clinical trial to assess the reactogenicity, safety and immunogenicity of a SIIPL DTwP-HepB-rPV-Hib vaccine in comparison with HEXASIIL® in healthy…
- Conditions
- Diptheria Immunization, Tetanus Immunization, Pertussis Immunization, Hepatitis B Immunization
- Trial name
- NCT07855172
- Testing
- Hexavalent (DTwP-HepB-rPV-Hib) Vaccine, HEXASIIL
- Where
- Bangladesh
- Volunteers
- 186 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.